| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Yu Jeffrey | Chief Medical Officer, Director | 6385 OLD SHADY OAK ROAD, SUITE 250, EDEN PRAIRIE | /s/ Robert Golden, Attorney-in-Fact | 26 Nov 2025 | 0001991132 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ONMD | Common Stock | Purchase | $4.32K | +3.3K | +0.13% | $1.31 | 2.46M | 08 Dec 2023 | Direct | F1 |
| transaction | ONMD | Common Stock | Purchase | $40.80 | +30 | +0% | $1.36 | 2.46M | 11 Dec 2023 | Direct | F2 |
| transaction | ONMD | Common Stock | Purchase | $3.22K | +3.04K | +0.12% | $1.06 | 2.46M | 12 Dec 2023 | Direct | F3 |
| transaction | ONMD | Common Stock | Purchase | $54.50 | +50 | +0% | $1.09 | 2.46M | 13 Dec 2023 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $9.20 | +10 | +0% | $0.92 | 2.46M | 15 Dec 2023 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $10.30 | +10 | +0% | $1.03 | 2.46M | 27 Dec 2023 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $16.40 | +20 | +0% | $0.82 | 2.46M | 02 Jan 2024 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $151 | +180 | +0.01% | $0.84 | 2.46M | 04 Jan 2024 | Direct | F4 |
| transaction | ONMD | Common Stock | Purchase | $8.30 | +10 | +0% | $0.83 | 2.46M | 08 Jan 2024 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $86.00 | +100 | +0% | $0.86 | 2.46M | 09 Jan 2024 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $17.00 | +20 | +0% | $0.85 | 2.46M | 10 Jan 2024 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $16.20 | +20 | +0% | $0.81 | 2.46M | 12 Jan 2024 | Direct | |
| transaction | ONMD | Common Stock | Purchase | $11.30 | +15 | +0% | $0.75 | 2.46M | 16 Jan 2024 | Direct | F5 |
| transaction | ONMD | Common Stock | Purchase | $221 | +362 | +0.01% | $0.61 | 2.46M | 17 Jan 2024 | Direct | F6 |
| transaction | ONMD | Common Stock | Purchase | $28.80 | +60 | +0% | $0.48 | 2.46M | 19 Jan 2024 | Direct | F7 |
| transaction | ONMD | Common Stock | Award | $0 | +45K | +1.83% | $0.00 | 2.51M | 19 Jan 2024 | Direct | F15 |
| transaction | ONMD | Common Stock | Purchase | $2.47K | +5.04K | +0.2% | $0.49 | 2.51M | 22 Jan 2024 | Direct | F8 |
| transaction | ONMD | Common Stock | Purchase | $374 | +720 | +0.03% | $0.52 | 2.51M | 23 Jan 2024 | Direct | F9 |
| transaction | ONMD | Common Stock | Purchase | $407 | +740 | +0.03% | $0.55 | 2.51M | 24 Jan 2024 | Direct | F10 |
| transaction | ONMD | Common Stock | Purchase | $1.27K | +2.3K | +0.09% | $0.55 | 2.52M | 25 Jan 2024 | Direct | F11 |
| transaction | ONMD | Common Stock | Purchase | $3.02K | +5.39K | +0.21% | $0.56 | 2.52M | 26 Jan 2024 | Direct | F12 |
| transaction | ONMD | Common Stock | Purchase | $988 | +950 | +0.04% | $1.04 | 2.52M | 29 Jan 2024 | Direct | F13 |
| transaction | ONMD | Common Stock | Purchase | $456 | +400 | +0.02% | $1.14 | 2.52M | 30 Jan 2024 | Direct | F14 |
| holding | ONMD | Common Stock | 1.31M | 08 Dec 2023 | By trust for children | F16 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.28 to $1.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.35 to $1.37, inclusive. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.71 to $0.78, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.56 to $0.73, inclusive. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive. |
| F9 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.48 to $0.54, inclusive. |
| F10 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.52 to $0.60, inclusive. |
| F11 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.50 to $0.60, inclusive. |
| F12 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.51 to $0.60, inclusive. |
| F13 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.07, inclusive. |
| F14 | The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.48, inclusive. |
| F15 | Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024. |
| F16 | The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose. |